Cargando…

Dopamine Agonists and Pathologic Behaviors

The dopamine agonists ropinirole and pramipexole exhibit highly specific affinity for the cerebral dopamine D3 receptor. Use of these medications in Parkinson's disease has been complicated by the emergence of pathologic behavioral patterns such as hypersexuality, pathologic gambling, excessive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelley, Brendan J., Duker, Andrew P., Chiu, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328150/ https://www.ncbi.nlm.nih.gov/pubmed/22567537 http://dx.doi.org/10.1155/2012/603631

Ejemplares similares

Pathological gambling and dopamine agonists: A phenotype?
por: Pinder, Roger M
Publicado: (2007)

Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia
por: Abe, Yoshifumi, et al.
Publicado: (2023)

Publicity and reports of behavioral addictions associated with dopamine agonists
por: Gendreau, Katherine E., et al.
Publicado: (2016)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

Dopamine, behavior, and addiction
por: Wise, Roy A., et al.
Publicado: (2021)

Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists
por: Mohammad, Mohammad Edrees, et al.
Publicado: (2021)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

Dopamine Agonists and Impulse Control Disorders: A Complex Association
por: Grall-Bronnec, Marie, et al.
Publicado: (2017)

The effects of dopamine and dopamine receptor agonists on the phototransduction cascade of frog rods
por: Nikolaeva, Darya A., et al.
Publicado: (2019)

Impulse control disorders and dopamine agonists
por: Martins, D., et al.
Publicado: (2021)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

Predictors of dopamine agonist resistance in prolactinoma patients
por: Vermeulen, Elle, et al.
Publicado: (2020)

Prevalence of hypersexual behavior in Parkinson’s disease patients: Not restricted to males and dopamine agonist use
por: Cooper, Christine A, et al.
Publicado: (2009)

Impairment of Macroautophagy in Dopamine Neurons Has Opposing Effects on Parkinsonian Pathology and Behavior
por: Hunn, Benjamin H.M., et al.
Publicado: (2019)

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists
por: Pogorelov, Vladimir M., et al.
Publicado: (2023)

Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
por: Costa, M.L., et al.
Publicado: (2022)

Role of dopamine and selective dopamine receptor agonists on mouse ductus arteriosus tone and responsiveness
por: Crockett, Stacey L., et al.
Publicado: (2019)

Non-ergot dopamine agonists and heart failure
por: Şener, Yusuf Ziya, et al.
Publicado: (2019)

Dopamine agonist resistant prolactinomas: any alternative medical treatment?
por: Souteiro, P., et al.
Publicado: (2019)

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
por: Frazer, Monica, et al.
Publicado: (2022)

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
por: Isaacson, Stuart H., et al.
Publicado: (2023)

The effects of dopamine receptor 1 and 2 agonists and antagonists on sexual and aggressive behaviors in male green anoles
por: Smith, Alexandra N., et al.
Publicado: (2017)

Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia
por: Hollingworth, Samantha A., et al.
Publicado: (2015)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
por: Pivonello, Claudia, et al.
Publicado: (2022)

Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment
por: Ersche, Karen D., et al.
Publicado: (2010)

Successful treatment of dopamine dysregulation syndrome with dopamine D(2) partial agonist antipsychotic drug
por: Mizushima, Jin, et al.
Publicado: (2012)

Dopamine Agonist-Resistant Microprolactinoma—Mechanisms, Predictors and Management: A Case Report and Literature Review
por: Szmygin, Hanna, et al.
Publicado: (2022)

Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis
por: Mendoza-Torreblanca, Julieta Griselda, et al.
Publicado: (2023)

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
por: De Sousa, Sunita M C
Publicado: (2022)

Detecting associations between behavioral addictions and dopamine agonists in the Food & Drug Administration’s Adverse Event database
por: Gendreau, Katherine E., et al.
Publicado: (2014)

Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
por: Talty, Ronan, et al.
Publicado: (2022)

Dopamine, Behavioral Economics, and Effort
por: Salamone, John D., et al.
Publicado: (2009)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists
por: Babey, Muriel, et al.
Publicado: (2010)

The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke
por: Gorgoraptis, Nikos, et al.
Publicado: (2012)

Dopamine modulation of sensory processing and adaptive behavior in flies
por: Siju, K. P., et al.
Publicado: (2021)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease
por: Picillo, Marina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jhhuf49bhakuj2uspqavoftf4n